BRISTOL-MYERS SQUIBB's PARAPLATIN (CARBOPLATIN) DATA SUPPORT FIRST-LINE OVARIAN CANCER INDICATION DESPITE SURVIVAL PROFILE CONCERNS, FDA FINDS